COREY CARR: Open Payments
NPI 1831760909 · VISALIA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$403 in 16 payments from 10 companies in 2025. Trend: 2023 $50 · 2024 $600 · 2025 $403
Food & beverage: $403
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 6 | $170 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $49 |
| Novartis Pharmaceuticals Corporation | 1 | $30 |
| Smith+Nephew, Inc. | 1 | $28 |
| GENZYME CORPORATION | 1 | $26 |
| AstraZeneca Pharmaceuticals LP | 1 | $23 |
| GlaxoSmithKline, LLC. | 1 | $23 |
| Lilly USA, LLC | 1 | $19 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $19 |
| Novo Nordisk Inc | 1 | $15 |
Products named: DUPIXENT, NEFFY, Rhapsido, AIRSUPRA, NUCALA, ZEPBOUND, JOURNAVX.
Industry payments across CA — which companies pay providers there.
